rebetol capsule 200 mg
msd pharma (singapore) pte. ltd. - ribavirin - capsule - 200 mg - ribavirin 200 mg
zoely film-coated tablet 2.5mg/1.5mg
msd pharma (singapore) pte. ltd. - estradiol hemihydrate 1.55mg eqv estradiol - tablet, film coated - 1.50mg
kalydeco ivacaftor 75 mg granules sachet
vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 75 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).
kalydeco ivacaftor 50 mg granules sachet
vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 50 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).
enstilar calcipotriol (as monohydrate) 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g foam aerosol can
leo pharma pty ltd - calcipotriol, quantity: 20.5 microgram/g; betamethasone dipropionate, quantity: 264 microgram/g (equivalent: betamethasone, qty 205 microgram/g) - foam - excipient ingredients: polyoxypropylene-11 stearyl ether; liquid paraffin; dl-alpha-tocopherol; white soft paraffin; butane; methyl ether - enstilar is indicated for the topical treatment of psoriasis vulgaris in adults.
kalydeco ivacaftor 150mg film-coated tablets blister pack
vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: carnauba wax; croscarmellose sodium; silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)
kalydeco ivacaftor 150mg film-coated tablets bottle
vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; silicon dioxide; carnauba wax; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)
mycophenolate an mycophenolate mofetil 500mg tablet blister pack
amneal pharma australia pty ltd - mycophenolate mofetil -
candesartan cilexetil and hydrochlorothiazide tablet
macleods pharmaceuticals limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexitil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexitil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j
entacapone tablet
macleods pharmaceuticals limited - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone tablets are not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.